Combination targeted therapy for advanced esophageal cancer
Part of Cancer, Digestive system clinical trials.
This study tests a new combination of two drugs (sacituzumab tirumotecan and another drug) for people with advanced esophageal cancer. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have esophageal squamous cell carcinoma that has spread, come back, or cannot be removed with surgery.
- You have not had any cancer treatment before, OR you had one line of chemotherapy (with or without immunotherapy) that stopped working or caused bad side effects.
- If you have brain metastases, they must be stable and not causing symptoms.
- You are able to do daily activities (ECOG 0 or 1) and expected to live at least 3 months.
- Your liver, kidney, and blood counts are within acceptable levels, and you can swallow pills.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs for advanced esophageal cancer that has grown despite earlier treatment. The goal is to see if this combination can help shrink tumors and slow the disease.
This trial tests two drugs, sacituzumab tirumotecan and toripalimab, given before surgery for esophageal cancer that has spread nearby but is still removable. The goal is to see if this combination shrinks the tumor and improves outcomes.
This trial tests a drug called sacituzumab govitecan for people with advanced esophageal squamous cell carcinoma that has already been treated with chemotherapy and immunotherapy. The drug targets a protein called Trop-2 on cancer cells to try to stop tumor growth.
This trial tests a combination of two drugs, sacituzumab tirumotecan and tagitanlimab, for people with advanced esophageal or stomach cancer that has progressed after initial treatment. The goal is to see if this combination can help control the cancer.
This trial tests a combination of two newer drugs (sacituzumab tirumotecan and anlotinib) for people with extensive-stage small cell lung cancer that has progressed after one prior treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new combination of two drugs for people with extensive-stage small cell lung cancer that has progressed after initial treatment. The goal is to see if this combination can help control the cancer.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.